Teoh, Deanna <br/><br/>
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.  [electronic resource] 

 -  Gynecologic oncology  Apr 2011 
 - 187-92 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2010.11.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carboplatin--administration & dosage<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Dasatinib<br/>Drug Synergism<br/>Female<br/>Gene Expression--drug effects<br/>Humans<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Proto-Oncogene Proteins pp60(c-src)--biosynthesis<br/>Pyrimidines--administration & dosage<br/>Thiazoles--administration & dosage